Tatva Chintan Pharma IPO Subscribed Over 180 Times On Final Day Of Issue

INSUBCONTINENT EXCLUSIVE:
shareholders
manufacturing company will utilise the IPO proceeds to fund its capital expenditure requirements, expand its Dahej manufacturing
in topline (CAGR of 26 per cent) over the last three years, backed by expansion in its product portfolio due to R-D initiatives
The company has also reported healthy margins and return ratios
Tatva Chintan's margins have also expanded over the last three years
It is the largest and only commercial manufacturer of SDAs for zeolites in India
of 49.5 times FY21 EPS (on a fully diluted on post-issue basis)
This is lower as compared to peers such as Fine Organics (75 times), Vinati Organics (77 times) and Navin Fluorine (73 times)
robust return ratios, good growth visibility, leadership position, and reasonable valuations, we remain positive on the prospects of this
issue," SEBI-registered investment advisor INDmoney said in a report.